Inventiva S.A. (IVA.PA)
EUR 2.15
(2.38%)
EUR 2.15
(2.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 37.4 Million EUR | 8.38% |
| 2022 | 34.51 Million EUR | 241.08% |
| 2021 | 10.11 Million EUR | -23.65% |
| 2020 | 13.25 Million EUR | 530.54% |
| 2019 | 2.1 Million EUR | -4.58% |
| 2018 | 2.2 Million EUR | 356.99% |
| 2017 | 482.06 Thousand EUR | -23.19% |
| 2016 | 627.6 Thousand EUR | -10.09% |
| 2015 | 698 Thousand EUR | 568.19% |
| 2014 | 104.46 Thousand EUR | -34.87% |
| 2013 | 160.39 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q4 | 37.4 Million EUR | 0.0% |
| 2023 FY | 37.4 Million EUR | 8.38% |
| 2023 Q2 | 35.13 Million EUR | 0.0% |
| 2022 FY | 34.51 Million EUR | 241.08% |
| 2022 Q2 | 18.53 Million EUR | 0.0% |
| 2022 Q4 | 34.51 Million EUR | 0.0% |
| 2021 FY | 10.11 Million EUR | -23.65% |
| 2021 Q1 | 13.28 Million EUR | 0.23% |
| 2021 Q2 | 10.09 Million EUR | -24.02% |
| 2021 Q4 | 10.11 Million EUR | 0.0% |
| 2020 FY | 13.25 Million EUR | 530.54% |
| 2020 Q2 | 12 Million EUR | 0.0% |
| 2020 Q4 | 13.25 Million EUR | 0.0% |
| 2019 Q4 | 2.1 Million EUR | 0.0% |
| 2019 FY | 2.1 Million EUR | -4.58% |
| 2019 Q2 | 2.24 Million EUR | 0.0% |
| 2018 Q4 | 2.2 Million EUR | 0.0% |
| 2018 FY | 2.2 Million EUR | 356.99% |
| 2018 Q2 | 296.48 Thousand EUR | 0.0% |
| 2017 FY | 482.06 Thousand EUR | -23.19% |
| 2017 Q4 | 482.06 Thousand EUR | 0.0% |
| 2017 Q2 | 550.48 Thousand EUR | 0.0% |
| 2016 Q4 | 627.6 Thousand EUR | 0.0% |
| 2016 FY | 627.6 Thousand EUR | -10.09% |
| 2016 Q2 | 714.08 Thousand EUR | 0.0% |
| 2015 FY | 698 Thousand EUR | 568.19% |
| 2015 Q4 | 698 Thousand EUR | 0.0% |
| 2014 FY | 104.46 Thousand EUR | -34.87% |
| 2013 FY | 160.39 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -1003.451% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 32.556% |
| Adocia SA | 13.08 Million EUR | -185.811% |
| Aelis Farma SA | 4.03 Million EUR | -826.374% |
| Biophytis S.A. | 8.27 Million EUR | -352.322% |
| Advicenne S.A. | 17.42 Million EUR | -114.674% |
| genOway Société anonyme | 7.23 Million EUR | -417.142% |
| IntegraGen SA | 1.12 Million EUR | -3225.85% |
| Medesis Pharma S.A. | 1.2 Million EUR | -3017.25% |
| Neovacs S.A. | 650 Thousand EUR | -5654.923% |
| NFL Biosciences SA | 62.17 Thousand EUR | -60065.021% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -758.646% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -1276.857% |
| Sensorion SA | 2.86 Million EUR | -1203.931% |
| Theranexus Société Anonyme | 3.64 Million EUR | -926.813% |
| TME Pharma N.V. | 1.16 Million EUR | -3108.148% |
| Valbiotis SA | 6.87 Million EUR | -443.864% |
| TheraVet SA | 1.15 Million EUR | -3125.111% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -315.726% |
| argenx SE | 18.1 Million EUR | -106.608% |
| BioSenic S.A. | 28.16 Million EUR | -32.833% |
| Celyad Oncology SA | 902 Thousand EUR | -4047.118% |
| DBV Technologies S.A. | 13.01 Million USD | -187.335% |
| Galapagos NV | 9.59 Million EUR | -289.819% |
| Genfit S.A. | 70.17 Million EUR | 46.697% |
| GeNeuro SA | 7.73 Million EUR | -383.432% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -606.592% |
| Innate Pharma S.A. | 39.89 Million EUR | 6.232% |
| MaaT Pharma SA | 14.07 Million EUR | -165.769% |
| MedinCell S.A. | 58.96 Million EUR | 36.556% |
| Nanobiotix S.A. | 50.56 Million EUR | 26.022% |
| Onward Medical N.V. | 16.87 Million EUR | -121.684% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -173.298% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 18.327% |
| Oxurion NV | 12.33 Million EUR | -203.284% |
| Pharming Group N.V. | 155.29 Million EUR | 75.912% |
| Poxel S.A. | 46.9 Million EUR | 20.241% |
| GenSight Biologics S.A. | 18.42 Million EUR | -102.99% |
| Transgene SA | 1.25 Million EUR | -2875.895% |
| Financière de Tubize SA | 79.2 Million EUR | 52.769% |
| UCB SA | 3.03 Billion EUR | 98.769% |
| Valneva SE | 208.81 Million EUR | 82.086% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -98339.474% |